C Difficile

9822 bookmarks
Newest
[Clostridioides difficile infection diagnosed by nucleic acid amplification test in a patient with Epstein-Barr Virus-related T-cell lymphoproliferative disorder] - PubMed
[Clostridioides difficile infection diagnosed by nucleic acid amplification test in a patient with Epstein-Barr Virus-related T-cell lymphoproliferative disorder] - PubMed
Steroid usage poses a risk of Clostridioides difficile infection (CDI), but high-dose corticosteroid treatment can lead to false-negative CD toxin test results. Moreover, CDI-induced nausea can complicate administration of oral antibiotics, which are typically the primary therapy for CDI. In the pre …
·pubmed.ncbi.nlm.nih.gov·
[Clostridioides difficile infection diagnosed by nucleic acid amplification test in a patient with Epstein-Barr Virus-related T-cell lymphoproliferative disorder] - PubMed
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Biofilm formation and toxin production are some of the virulence factors of Clostridioides difficile (C. difficile), which causes hospital-acquired C. difficile infection (HA-CDI). This work investigated the prevalence and distribution of different strains recovered from HA-CDI patients hospitalized …
·pubmed.ncbi.nlm.nih.gov·
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Patients with IBD have an increased risk for Clostridioides difficile infection (CDI), which can lead to worse IBD outcomes. The diagnosis of CDI in IBD patients is complicated by higher C. difficile colonization rates and shared clinical symptoms of intestinal inflammation. Traditional risk factors …
·pubmed.ncbi.nlm.nih.gov·
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
The potential role of nemonoxacin, which can be administered parenterally, for treating CDIs was evidenced through the in vitro, ex vivo, and mouse models.
·pubmed.ncbi.nlm.nih.gov·
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
Scientific Reports - Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
·nature.com·
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Patients with IBD have an increased risk for Clostridioides difficile infection (CDI), which can lead to worse IBD outcomes. The diagnosis of CDI in IBD patients is complicated by higher C. difficile colonization rates and shared clinical symptoms of intestinal inflammation. Traditional risk factors …
·pubmed.ncbi.nlm.nih.gov·
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Human microbiome: Impact of newly approved treatments on C. difficile infection - PubMed
Human microbiome: Impact of newly approved treatments on C. difficile infection - PubMed
Live microbiome therapy is a promising solution for patients with recurrent CDI. Future studies should provide further evidence within yet-to-be-evaluated populations not included in registry studies. This along with real-world evidence will inform future use and clinical guideline placement.
·pubmed.ncbi.nlm.nih.gov·
Human microbiome: Impact of newly approved treatments on C. difficile infection - PubMed
Infection Prevention Leadership Search: Insights and Advice From Tamara Behm, MSN, RN, CIC, FAPIC, CER, CQIA, CCSVP, CAIP
Infection Prevention Leadership Search: Insights and Advice From Tamara Behm, MSN, RN, CIC, FAPIC, CER, CQIA, CCSVP, CAIP
Discover Tamara Behm's journey in seeking an IP leadership role, her passion for patient safety, and advice for job-seeking professionals in infection prevention, in this discussion with ICT’s IPLifeline.
·infectioncontroltoday.com·
Infection Prevention Leadership Search: Insights and Advice From Tamara Behm, MSN, RN, CIC, FAPIC, CER, CQIA, CCSVP, CAIP
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
The potential role of nemonoxacin, which can be administered parenterally, for treating CDIs was evidenced through the in vitro, ex vivo, and mouse models.
·pubmed.ncbi.nlm.nih.gov·
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copay …
·pubmed.ncbi.nlm.nih.gov·
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics - PubMed
Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics - PubMed
Clostridioides difficile is a major nosocomial pathogen, causing significant morbidity and mortality worldwide. Antibiotic usage, a major risk factor for Clostridioides difficile infection (CDI), disrupts the gut microbiota, allowing C. difficile to proliferate and cause infecti …
·pubmed.ncbi.nlm.nih.gov·
Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics - PubMed
Development and evaluation of a rapid visual loop-mediated isothermal amplification assay for the tcdA gene in Clostridioides difficile detection - PubMed
Development and evaluation of a rapid visual loop-mediated isothermal amplification assay for the tcdA gene in Clostridioides difficile detection - PubMed
LAMP method is an effective technique for the rapid and visual detection of the tcdA gene of C. difficile, and shows potential advantages over PCR in terms of speed, simplicity, and sensitivity. The tcdA-LAMP assay is particularly suitable for medical diagnostic environments wit …
·pubmed.ncbi.nlm.nih.gov·
Development and evaluation of a rapid visual loop-mediated isothermal amplification assay for the tcdA gene in Clostridioides difficile detection - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copay …
·pubmed.ncbi.nlm.nih.gov·
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
How to develop a Controlled Human Infection Model for Clostridioides difficile - PubMed
How to develop a Controlled Human Infection Model for Clostridioides difficile - PubMed
Should these challenges be tackled, a C. difficile CHIM not only provides a way forward for the testing of novel products but also offers a framework for better understanding of the pathophysiology, pathogenesis and immunology of C. difficile colonisation and infection.
·pubmed.ncbi.nlm.nih.gov·
How to develop a Controlled Human Infection Model for Clostridioides difficile - PubMed